Annovis Bio, Inc.
ANVS evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $58.9M
- Lead Asset:
- ANVS405 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ANVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANVS
Annovis Bio, Inc. (ANVS) is a Phase 3 clinical-stage biotechnology company developing buntanetap, an oral therapy for Alzheimer's and Parkinson's diseases, with a fully enrolled pivotal Phase 3 Alzheimer's trial and ongoing Parkinson's studies.
Key risk: Negative equity
BioSniper Score
Based on 4 of 6 signals
Market Cap
$58.9M
Cash Runway
—
Lead Asset
ANVS405 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Annovis Bio, Inc..
Annovis Bio, Inc. (ANVS) is a Phase 3 clinical-stage biotechnology company developing buntanetap, an oral therapy for Alzheimer's and Parkinson's diseases, with a fully enrolled pivotal Phase 3 Alzheimer's trial and ongoing Parkinson's studies.
- Phase 3 clinical-stage company developing buntanetap for Alzheimer's and Parkinson's diseases [news · 2026-08-25]
- Pivotal Phase 3 Alzheimer's trial fully enrolled with 850 patients; symptomatic data readout expected Q1 2027 [news · 2026-07-07]
- Cash & equivalents of $18.7M as of 2026-06-30 [sec]
- Net income of -$14.8M and shareholders' equity of -$4.3M as of 2026-06-30 [sec]
- Phase 2/3 Alzheimer's results published in Nature Portfolio showed improved cognition in pTau217-positive early AD patients [news · 2026-04-28]
What works
- Fully enrolled pivotal Phase 3 Alzheimer's trial (850 patients) exceeding original projections, with DSMB safety approval at 6 months [news · 2026-07-07][news · 2026-02-12]
- Buntanetap is an oral translational inhibitor of multiple neurotoxic proteins (APP, tau, αSYN), potentially offering a disease-modifying approach [sec_mda · as of 2026-08-14][pipeline]
- Phase 2/3 results published in Nature Portfolio showed improved cognition and reduced biomarkers of neuroinflammation and neurodegeneration [news · 2026-04-28]
- Company plans rolling NDA for symptomatic Alzheimer's treatment in early 2027 and disease-modifying NDA in early 2028 [news · 2026-05-15]
What to weigh
- Negative shareholders' equity of -$4.3M as of 2026-06-30 indicates liabilities exceed assets [sec]
- Net loss of $14.8M in the latest reported period (as of 2026-06-30) with no approved product revenue [sec]
- Cash runway limited to $18.7M as of 2026-06-30, which may need to cover operations until potential NDA approvals in 2027-2028 [sec][news · 2026-05-15]
- Phase 3 Alzheimer's trial results are not yet available; symptomatic data readout expected in Q1 2027, with no guarantee of efficacy [news · 2026-07-07]
From the filings
Quoted directly from source documents.
Pivotal Phase 3 Alzheimer's trial fully enrolled with 850 patients
“Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.”
News · August 14, 2026
Buntanetap improved cognition in pTau217-positive early AD patients
“Buntanetap improved cognition in pTau217-positive early AD patients”
News · April 28, 2026
DSMB positive recommendation at 6 months for buntanetap safety
“an independent Data and Safety Monitoring Board (DSMB) has issued a positive recommendation regarding the safety of buntanetap at 6 months”
News · February 12, 2026
Catalyst timeline
- 2025-02-04 · Phase3_Start: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease — Initiation of the pivotal Phase 3 Alzheimer's trial; symptomatic data readout expected Q1 2027.
- 2026-01-09 · Phase3_Start: An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease — Open-label extension study for Parkinson's disease; full enrollment projected Q4 2026.
- 2026-09-21 · Phase3_Start: An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Alzheimer's Disease — Open-label extension study for Alzheimer's disease; long-term safety data collection.
Risks & what to watch (4)›
Key risks
- Negative equity — Shareholders' equity of -$4.3M as of 2026-06-30 indicates liabilities exceed assets [sec]
- No approved product — Company has no marketed product; revenue is zero and net loss is $14.8M as of 2026-06-30 [sec]
- Clinical trial risk — Phase 3 Alzheimer's symptomatic data readout not until Q1 2027; efficacy not guaranteed [news · 2026-07-07]
- Cash runway — Cash of $18.7M as of 2026-06-30 may be insufficient to fund operations until potential NDA approvals in 2027-2028 [sec][news · 2026-05-15]
What to watch
- Symptomatic data readout from Phase 3 Alzheimer's trial expected in Q1 2027 [news · 2026-07-07]
- Rolling NDA submission for symptomatic Alzheimer's treatment could begin in May 2027 if efficacy requirements met [news · 2026-09-03]
- Parkinson's disease open-label extension study full enrollment projected in Q4 2026 [news · 2026-08-14]
- Corporate update webinar on September 2, 2026 may provide further clinical and financial updates [news · 2026-08-25]
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Annovis Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Annovis Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$15M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$10.3M
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 1,187,499 | $2.6M |
| vanguard capital management llc | 872,381 | $1.9M |
| two sigma investments, lp | 627,659 | $1.4M |
| renaissance technologies llc | 347,600 | $775K |
| geode capital management, llc | 247,513 | $552K |
| susquehanna international group, llp | 218,336 | $487K |
| northern trust corp | 141,730 | $316K |
| blackrock, inc. | 139,533 | $311K |
| vanguard fiduciary trust co | 132,042 | $294K |
| merit financial group, llc | 81,316 | $181K |
Showing top 10 of 56 institutional holders of Annovis Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 15.6%
- Days to cover
- 3.7
- Shares short
- 4,816,770
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Annovis Bio, Inc.?
Annovis Bio, Inc. (ANVS) is a Phase 3 clinical-stage biotechnology company developing buntanetap, an oral therapy for Alzheimer's and Parkinson's diseases, with a fully enrolled pivotal Phase 3 Alzheimer's trial and ongoing Parkinson's studies.
What is Annovis Bio, Inc.'s lead drug candidate?
Annovis Bio, Inc.'s most advanced tracked candidate is ANVS405 (Preclinical) for traumatic brain injury.
Who is the CEO of Annovis Bio, Inc.?
Dr. Maria L. Maccecchini Ph.D. is the chief executive officer of Annovis Bio, Inc. (ANVS).
Where is Annovis Bio, Inc. headquartered?
Annovis Bio, Inc. (ANVS) is headquartered in Malvern, PA, United States.
What therapeutic areas does Annovis Bio, Inc. focus on?
Annovis Bio, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.